← Back to Search

Medication Optimization Intervention for HIV/AIDS (HIV-MOI Trial)

N/A
Waitlist Available
Led By Marc L Fleming, PhD
Research Sponsored by University of North Texas Health Science Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older
At least one of the following: hypertension or diabetes type 2
Must not have
Refusal to provide medical record release
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare the health outcomes of two groups of African-Americans with HIV who either receive medication optimization with access to their medical records or usual care without access to records.

Who is the study for?
This trial is for adult African-Americans with HIV who also have high blood pressure, type 2 diabetes, or both. Participants must be willing to share their medical records and not be pregnant or have a life expectancy of less than 2 years.
What is being tested?
The study tests if pharmacists improve health outcomes by accessing patients' medical records. Half will receive 'medication optimization' based on full records, while the other half gets standard counseling without record access.
What are the potential side effects?
Since this trial involves medication optimization rather than new drugs, side effects are not a primary concern; however, changes in medication management could potentially lead to typical drug-related side effects depending on individual treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have either high blood pressure or type 2 diabetes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I refuse to allow access to my medical records.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Diabetes mellitus
Hypertension

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Medication Optimization InterventionExperimental Treatment1 Intervention
This group will represent those participants whose medical records have been provided to the pharmacist.
Group II: Medication Optimization ControlActive Control1 Intervention
This group will represent those participants whose medical records have not been provided to the pharmacist.

Find a Location

Who is running the clinical trial?

University of North Texas Health Science CenterLead Sponsor
40 Previous Clinical Trials
20,638 Total Patients Enrolled
University of MinnesotaOTHER
1,428 Previous Clinical Trials
1,620,544 Total Patients Enrolled
3 Trials studying Diabetes
834 Patients Enrolled for Diabetes
Walgreens, A Boots AllianceUNKNOWN

Media Library

Medication optimization intervention Clinical Trial Eligibility Overview. Trial Name: NCT03437694 — N/A
Diabetes Research Study Groups: Medication Optimization Control, Medication Optimization Intervention
Diabetes Clinical Trial 2023: Medication optimization intervention Highlights & Side Effects. Trial Name: NCT03437694 — N/A
Medication optimization intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT03437694 — N/A
~18 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top